All Mara Klöhn articles
-
NewsPromising active substance against hepatitis E identified
A drug that is already in clinical trials against hepatitis C virus can also prevent hepatitis E virus from replicating An international research team has filtered bemnifosbuvir, a nucleotide/nucleoside analogue, out of a library of active substances.
-
NewsStudy paves the way for an active agent against hepatitis E
Tests in cell culture with human liver cells showed that the compound K11777 prevents infection with hepatitis E viruses.
-
NewsSingle hepatitis E mutation renders sofosbuvir therapy ineffective
A single mutation of the hepatitis E virus has been shown to cause treatment with the hepatitis C drug sofosbuvir to become much less effective, according to a study that provides new insights for future drug development.